NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study in pediatric patients with inhibitors reported a decrease in the total ...

GAITHERSBURG, Md., US, November 7, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

Leveraging AI Efficiencies Reduced Quarterly Operating Expenses from $22M to $6M, Reduced Staff from 350 to 95 ...

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (R) (bimekizumab-bkzx) in adults with active ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, Nov. 13, 2025 /CNW/ ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of ...